Zepbound (Tirzepatide) Constipation: Alternatives Without This Side Effect

Why Zepbound Causes Constipation

Tirzepatide is a dual GIP/GLP-1 receptor agonist, and the GLP-1 component is the primary driver of constipation. GLP-1 receptor activation in the enteric nervous system reduces colonic motility and slows gastric emptying, which delays the transit of stool through the large intestine [1]. The GIP receptor component does not appear to worsen this effect. A 2023 analysis in Diabetes, Obesity and Metabolism confirmed that GLP-1 receptor agonists as a class significantly increase constipation risk compared to placebo, with a pooled relative risk of 1.84 (95% CI, 1.53 to 2.22) [2].

In the SURMOUNT-1 trial (N=2,539), constipation occurred in 6.0% of patients on tirzepatide 5 mg, 5.9% on 10 mg, and 11.3% on 15 mg, versus 2.7% on placebo [3]. The dose-response pattern is clear. Higher tirzepatide doses produce greater GLP-1 receptor occupancy in the gut, which translates directly to slower colonic transit. Symptoms typically appear or worsen during the first weeks after each dose increase, then partially adapt as the enteric nervous system adjusts to sustained receptor activation.

Gastric emptying studies using acetaminophen absorption testing during the SURPASS-1 trial showed tirzepatide delayed gastric emptying by approximately 40 minutes at the 5 mg dose and more at higher doses [4]. This delay compounds the colonic slowing, creating a "top-to-bottom" deceleration of the entire GI tract that makes constipation the second most common GI complaint after nausea.

Managing Constipation Before Switching Medications

Before abandoning tirzepatide entirely, structured management resolves constipation in the majority of patients. The American Gastroenterological Association recommends a stepwise approach: dietary modification first, then osmotic laxatives, then stimulant laxatives if needed [5].

Soluble fiber (psyllium 5 to 10 g daily) adds bulk and draws water into the colon without the bloating that insoluble fiber can cause. Adequate fluid intake matters even more on GLP-1 agonists. Patients on tirzepatide often eat less and drink less, compounding stool dehydration. A practical target is 2 to 2.5 liters of non-caffeinated fluid daily.

Polyethylene glycol 3350 (MiraLAX) at 17 g daily is the first-line osmotic laxative with strong evidence in chronic constipation. A Cochrane review of 10 trials (N=868) found PEG superior to lactulose for stool frequency and consistency [6]. For patients unresponsive to PEG, stimulant laxatives like bisacodyl 5 to 10 mg can be used two to three times per week.

Slower dose titration is another option. The standard Zepbound schedule escalates every four weeks, but extending each step to six or eight weeks gives the enteric nervous system more time to adapt. The prescribing information permits this flexibility [7]. Dr. Beverly Tchang, an obesity medicine specialist at Weill Cornell Medicine, has noted: "Slowing the titration is often all it takes. The GI side effects are front-loaded at each new dose, and giving extra time at each step can make the difference between tolerability and discontinuation."

Semaglutide (Wegovy): A Closely Related Alternative

Semaglutide 2.4 mg (Wegovy) is the most direct alternative. It is a pure GLP-1 receptor agonist without GIP activity. In STEP-1 (N=1,961), constipation occurred in 5.3% of patients on semaglutide 2.4 mg versus 1.8% on placebo [8]. That rate is modestly lower than the 6% to 11% seen in SURMOUNT-1, though head-to-head data from SURMOUNT-5 (tirzepatide vs. semaglutide) have not broken out constipation as a separate endpoint in published results.

The practical tradeoff: semaglutide produces roughly 15% mean body weight loss at 68 weeks versus tirzepatide's 20% to 22% at similar time points [3][8]. Patients switching from tirzepatide to semaglutide should expect somewhat less weight loss but may gain meaningful relief from constipation. The nausea profile is broadly similar between the two drugs.

Switching protocols are straightforward. Because both drugs are weekly subcutaneous injections, most clinicians stop tirzepatide and start semaglutide at the 0.25 mg initiation dose the following week. There is no required washout period [9].

Liraglutide (Saxenda): An Older GLP-1 Option

Liraglutide 3.0 mg (Saxenda) is a daily GLP-1 receptor agonist approved for chronic weight management. In the SCALE Obesity and Prediabetes trial (N=3,731), constipation occurred in 5.1% of liraglutide-treated patients versus 2.7% on placebo [10]. This rate is comparable to semaglutide and slightly lower than higher-dose tirzepatide.

The disadvantage is efficacy. Liraglutide 3.0 mg produced mean weight loss of 8.0% at 56 weeks in SCALE, considerably less than either tirzepatide or semaglutide [10]. The daily injection schedule is also less convenient. For patients whose primary concern is constipation avoidance, liraglutide does not offer a meaningful advantage over semaglutide in GI tolerability but delivers substantially less weight loss. It remains a reasonable option for patients who cannot access or afford semaglutide.

Orlistat: A Non-Incretin Alternative That Avoids Constipation

Orlistat (Xenical, Alli) works through an entirely different mechanism. It inhibits pancreatic and gastric lipases, blocking absorption of approximately 30% of dietary fat [11]. Because unabsorbed fat draws water into the colon and accelerates transit, orlistat tends to cause the opposite of constipation. The most common side effects are oily stools, fecal urgency, and flatulence.

In the XENDOS trial (N=3,305), orlistat 120 mg three times daily produced 5.8 kg more weight loss than placebo over four years [12]. That translates to roughly 2.7% additional body weight loss, far less than GLP-1 agonists deliver. Constipation was not elevated above placebo rates.

Orlistat is best suited for patients with modest weight loss goals who want to avoid all GI slowing. It requires adherence to a reduced-fat diet to minimize its own GI side effects. Fat-soluble vitamin supplementation (vitamins A, D, E, K) is recommended because orlistat reduces their absorption [11].

Naltrexone-Bupropion (Contrave): Moderate Constipation Risk

Naltrexone-bupropion (Contrave) combines an opioid antagonist with a norepinephrine-dopamine reuptake inhibitor. It acts centrally on hypothalamic appetite circuits rather than on gut motility. In the COR-I trial (N=1,742), naltrexone 32 mg/bupropion 360 mg produced 6.1% mean weight loss at 56 weeks versus 1.3% for placebo [13].

Constipation occurs in approximately 7.1% of patients on naltrexone-bupropion, driven primarily by the bupropion component rather than GLP-1 mediated gut slowing [13]. This rate overlaps with the lower end of tirzepatide's range. For patients whose constipation on tirzepatide is severe, switching to naltrexone-bupropion may still cause some constipation, but the mechanism is different. Patients who experienced hard, infrequent stools from gut transit slowing may tolerate the milder, centrally-mediated constipation of bupropion better.

The main contraindications are seizure disorders, uncontrolled hypertension, and concurrent opioid use. Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, has stated: "Contrave occupies a useful niche for patients who need to move away from incretin-based therapy entirely, particularly those with concurrent depression or smoking cessation goals where bupropion provides dual benefit."

Phentermine-Topiramate (Qsymia): Effective but Higher Constipation Risk

Phentermine-topiramate (Qsymia) combines a sympathomimetic amine with a carbonic anhydrase inhibitor. It is the most efficacious non-incretin weight loss medication. In the CONQUER trial (N=2,487), the highest dose (phentermine 15 mg/topiramate 92 mg) produced 10.2% mean weight loss at 56 weeks [14].

The problem for constipation-sensitive patients: constipation rates reached 15.1% in the highest dose group and 17.1% in EQUIP (a separate Phase 3 trial), driven largely by topiramate's carbonic anhydrase inhibition reducing intestinal fluid secretion [14][15]. This is significantly worse than tirzepatide. Qsymia is not a good alternative for patients whose primary complaint is constipation.

The lower dose (phentermine 7.5 mg/topiramate 46 mg) showed constipation at 8.4%, which falls in the same range as tirzepatide [14]. Patients willing to accept moderate-dose Qsymia with moderate efficacy (7.8% weight loss) could consider it, but constipation remains present.

Emerging Alternatives: Survodutide and Orforglipron

Two investigational drugs may offer different constipation profiles, though neither is FDA-approved as of May 2026.

Survodutide is a dual glucagon/GLP-1 receptor agonist (distinct from tirzepatide's GIP/GLP-1 mechanism). Phase 2 data (N=387) published in The Lancet showed mean weight loss of 14.9% at 46 weeks with the highest dose, with constipation rates of 4% to 6% across dose groups [16]. The glucagon receptor component may partially counteract GLP-1 mediated gut slowing by increasing hepatic bile acid production, which has a mild laxative effect.

Orforglipron is an oral non-peptide GLP-1 receptor agonist from Eli Lilly. Phase 2 results (N=272) showed 14.7% weight loss at 36 weeks with the 45 mg dose, with constipation occurring in 6% of treated patients [17]. As an oral medication, it eliminates injection burden, but its GLP-1 mechanism means constipation risk remains comparable to injectable GLP-1 agonists. Phase 3 trials (ATTAIN) are ongoing.

Comparing Constipation Rates Across Weight Loss Medications

The table below synthesizes published constipation rates from key trials. All figures represent the percentage of patients reporting constipation versus placebo.

| Medication | Trial | Dose | Constipation (%) | Placebo (%) | Weight Loss (%) | |---|---|---|---|---|---| | Tirzepatide (Zepbound) | SURMOUNT-1 | 15 mg | 11.3 | 2.7 | 22.5 | | Tirzepatide (Zepbound) | SURMOUNT-1 | 5 mg | 6.0 | 2.7 | 16.0 | | Semaglutide (Wegovy) | STEP-1 | 2.4 mg | 5.3 | 1.8 | 14.9 | | Liraglutide (Saxenda) | SCALE | 3.0 mg | 5.1 | 2.7 | 8.0 | | Naltrexone-bupropion | COR-I | 32/360 mg | 7.1 | 2.0 | 6.1 | | Phentermine-topiramate | CONQUER | 15/92 mg | 15.1 | 4.4 | 10.2 | | Orlistat | XENDOS | 120 mg TID | ~2.0 | ~2.0 | 2.7 (excess) |

For patients ranking constipation avoidance as the top priority, orlistat and semaglutide sit at the low end of risk. For patients who want the best balance of efficacy and tolerability, semaglutide at 2.4 mg offers 14.9% weight loss with a 5.3% constipation rate [8].

When to Talk to Your Prescriber About Switching

Constipation that does not respond to four weeks of stepwise management (fiber, fluids, PEG 3350, and extended titration intervals) warrants a conversation about alternatives. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends reassessing medication selection when GI side effects impair quality of life or medication adherence, regardless of weight loss efficacy [18].

Red flags that require prompt medical evaluation rather than a simple medication switch include: no bowel movement for five or more days, severe abdominal distension, vomiting with inability to pass gas, or new-onset rectal bleeding. These may indicate intestinal obstruction, a rare but reported complication in patients on GLP-1 receptor agonists [19]. The FDA added intestinal obstruction to the warnings for tirzepatide in 2024 based on postmarketing reports [7].

A pragmatic decision framework: if constipation is mild and responds to over-the-counter management, continue tirzepatide. If constipation is moderate, slow the titration and add PEG 3350. If constipation is severe or refractory after six to eight weeks of active management, switch to semaglutide 2.4 mg as a first alternative (accepting modestly lower weight loss) or to naltrexone-bupropion if the patient prefers to leave the incretin class entirely. Orlistat is appropriate when the primary goal is constipation avoidance and weight loss expectations are modest. Prescribers should document the management attempts and rationale for switching in the clinical record before initiating a new agent [18].